Laplace Interventional, founded in Plymouth, MN, is a medical device company dedicated to developing innovative transcatheter tricuspid valve technology. The company's core mission is to enhance the life expectancy and quality of life for patients suffering from tricuspid regurgitation through minimally invasive procedures. Their primary product is a prosthetic valve designed to be delivered via a transcatheter approach, aiming to provide a less invasive alternative to traditional surgical methods.

Notable figures affiliated with Laplace Interventional include leading experts in cardiology and medical device innovation. The company has attracted significant interest from investors focused on advancing medical technologies. Key achievements include the development and ongoing refinement of their investigational device, which holds promise for transforming the treatment landscape for tricuspid regurgitation. Laplace Interventional's impact lies in its potential to offer a life-saving solution to a global patient population in need of advanced cardiac care.